赛诺菲鼻喷疫苗在中国获批临床，预防婴幼儿RSV感染

Investment Ratings - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as neutral [1][2]. Core Insights - The report maintains a positive outlook on the pharmaceutical industry, expecting returns to exceed the CSI 300 index by more than 5% over the next six months [7]. - Sanofi's RSV vaccine for infants has received clinical approval in China, indicating potential growth in the pediatric vaccine market [5][6]. Summary by Sections Industry Ratings - The pharmaceutical industry is rated as "positive," indicating an expectation of returns greater than 5% above the CSI 300 index in the next six months [7]. Market Performance - As of June 5, 2024, the pharmaceutical sector experienced a decline of 0.50%, outperforming the CSI 300 index by 0.08 percentage points, ranking fifth among 31 sub-industries [4]. Industry News - Sanofi's RSV vaccine, designed to prevent respiratory syncytial virus infections in infants aged 6 to 24 months, has been approved for clinical trials in China [5]. Company Announcements - Heng Rui Medicine's SHR-A1811 has been proposed for inclusion in the list of breakthrough therapies by the National Medical Products Administration [6]. - Rui Ang Gene's BCR-ABL P210 fusion gene detection kit has received a medical device registration certificate [6]. - Puli Pharmaceutical's gadobutrol injection has been approved for use as a contrast agent in MRI [6]. - Nuotai Bio's oseltamivir phosphate granules have received a drug registration certificate for treating and preventing influenza [6].